Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

This currently places CyberArk as the second most valuable Israeli company on Wall Street, after Check Point (which is also a ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...